Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-10994.73%
operating margin TTM
-11365.22%
revenue TTM
91.50 Million
revenue per share TTM
1.09$
valuation ratios | |
|---|---|
| pe ratio | -1.22 |
| peg ratio | 0.04 |
| price to book ratio | 2.37 |
| price to sales ratio | 137.17 |
| enterprise value multiple | -1.60 |
| price fair value | 2.37 |
profitability ratios | |
|---|---|
| gross profit margin | 41.77% |
| operating profit margin | -11365.22% |
| pretax profit margin | -10989.85% |
| net profit margin | -10994.73% |
| return on assets | -134.38% |
| return on equity | -135.81% |
| return on capital employed | -170.19% |
liquidity ratios | |
|---|---|
| current ratio | 4.50 |
| quick ratio | 4.46 |
| cash ratio | 2.63 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 422.99 |
| operating cycle | 434.24 |
| days of payables outstanding | 3,880.82 |
| cash conversion cycle | -3,446.58 |
| receivables turnover | 32.43 |
| payables turnover | 0.09 |
| inventory turnover | 0.86 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.10 |
| debt equity ratio | 0.13 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.12 |
| interest coverage | 0.00 |
| cash flow to debt ratio | -11.95 |
cash flow ratios | |
|---|---|
| free cash flow per share | -3.13 |
| cash per share | 2.09 |
| operating cash flow per share | -3.09 |
| free cash flow operating cash flow ratio | 1.01 |
| cash flow coverage ratios | -11.95 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | -67.14 |
Frequently Asked Questions
When was the last time EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) reported earnings?
EyePoint Pharmaceuticals, Inc. (EYPT) published its most recent earnings results on 05-08-2026.
What is EyePoint Pharmaceuticals, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)'s trailing twelve months ROE is -135.81%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. EyePoint Pharmaceuticals, Inc. (EYPT) currently has a ROA of -134.38%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did EYPT's net profit margin stand at?
EYPT reported a profit margin of -10994.73% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is EYPT's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 4.50 in the most recent quarter. The quick ratio stood at 4.46, with a Debt/Eq ratio of 0.13.